Exclusive supply agreement with Cannamedical in Germany

Highlights:

- LGP partners with German cannabis pioneer Cannamedical for the supply of bulk medicinal cannabis from Denmark to Germany, with a potential value of over $4.5 million (€3 million)[1] over two years

- LGP now has medicinal cannabis supply agreements with four key wholesalers and distributors in Germany, including three of the four largest independent, own-brand medicinal cannabis distributors in the country

- Agreement extends LGP's lead as the pre-eminent non-Canadian global medicinal cannabis group supplying products into Germany and the EU

- Agreement represents continued validation of LGP's key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions

Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce its wholly owned subsidiary, Little Green Pharma Denmark ApS ("**LGP Denmark**"), has entered into an agreement ("**Agreement**") with Cannamedical® Pharma GmbH ("**Cannamedical**") for the bulk supply of a high-THC strain ("**Product**") into Germany.

The Agreement represents LGP's fourth contract for the supply of medicinal cannabis into Germany and, together with Four20 Pharma, Illios Sante and Demecan, rounds out its wholesaling portfolio with the largest independent, own-brand medicinal cannabis distributor in Germany.

[1] EU:AUD 0.6557 as at 3 October 2022

Under the Agreement, LGP will exclusively supply the Product to Cannamedical for sale in Germany subject to Cannamedical ordering specified minimum quantities every six months to maintain exclusivity. In addition, the Product pricing contemplates a THC adjustment for every percentage point the THC content is above or below 22%, and with the payment terms requiring the upfront payment of a portion of the purchase price upon delivery.

Cannamedical

Cannamedical is a German-based pharmaceutical pioneer with licenses to import medicinal cannabis into Germany and distribute and export it within the European Union. Established in 2016, the company received the research seal "Innovative through Research" from the Federal Ministry of Education and Research (BMBF) and the International Life Science Award 2022 in the category "Best Medical Cannabis Products Supplier 2022 – Germany" in Q3 2022. Cannamedical has 25% of the German medical cannabis market, with the company's exponential year-over-year growth underpinned by a unique boutique product portfolio, long-term partnerships with innovative and carefully selected manufacturers, and the ability to leverage in-house manufacturing infrastructure. Since 2021, the company has been part of the Semdor Pharma Group – one of the leading specialty pharmaceutical groups in Europe specializing in narcotic and medicinal cannabis development, manufacturing, warehousing, and distribution.

Material terms

- LGP will develop the Product meeting agreed THC specifications and Cannamedical requirements

- Final development of the Product is expected within two to six months, with first shipment expected sometime between January and June 2023 depending on final Product licensing requirements

- The Agreement is subject to a number of conditions precedent, including entry into a QA Agreement, inclusion of LGP on Cannamedical narcotics licence, irradiation licences in Germany, and a successful audit of LGP Denmark's facilities; with the QA Agreement and Facility audit both well advanced and expected to be completed in the coming weeks

- All shipments are on FCA Incoterms from LGP's Danish facilities, with Cannamedical to arrange shipping and release in Germany

- The Agreement is a fixed priced contract with LGP entitled to refuse purchase orders for breach of payment terms or where otherwise reasonable

- LGP's sole liability for failure to achieve microbiological levels, late delivery, or failure to deliver, is re-delivery of the relevant shipment

ENDS
BY ORDER OF THE BOARD

_____
Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m^2 cultivation and 4,000m^2 GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp